Sponsors (12)
The bill creates a clearer, time-bound path for Medicaid value-based purchasing that could lower drug costs and improve access for beneficiaries, but it also risks higher list and Medicare prices, reduced rebates, administrative burdens, and potential access or competition harms that could offset some savings.
State Medicaid programs can adopt and expand value-based purchasing (VBP) for outpatient and inpatient drugs, enabling manufacturer payments tied to performance that may lower net drug costs for states, taxpayers, and Medicaid beneficiaries.
Provides regulatory clarity and predictable implementation timelines (HHS and OIG rulemakings within 180 days) so states, manufacturers, and third parties can design and adopt value-based agreements with reduced regulatory uncertainty.
Medicaid patients and other beneficiaries may get better access to effective therapies and improved health outcomes if VBP arrangements incentivize clinical performance and make transformative treatments more affordable.
Manufacturers may respond to VBP rules by raising list prices or changing reporting practices (e.g., multiple best price tactics), which could raise commercial baseline prices, reduce Medicaid rebates, and increase costs for patients and taxpayers.
Implementing new reporting, inter-state payment transfer arrangements, and compliance with HHS/OIG rules will create significant administrative and compliance burdens and short-term confusion for state Medicaid agencies, manufacturers, and hospitals.
Value-based payments could create perverse incentives or restrict access if manufacturers decline arrangements, negotiate restrictive terms, or withhold drugs for complex patients, harming some Medicaid beneficiaries' treatment options.
Based on analysis of 6 sections of legislative text.
Allows multi-point best-price reporting and creates legal and pricing changes to support value-based purchasing arrangements between manufacturers and States, plus safe harbor and studies.
Introduced March 9, 2026 by Brett Guthrie · Last progress March 9, 2026
Allows drug manufacturers to report multiple "best price" points when they offer value-based purchasing arrangements (VBPAs) to all States, adjusts how manufacturer prices are calculated for Medicaid and Medicare when drugs are sold under those arrangements, creates a safe harbor under the federal anti-kickback law for manufacturer payments to States tied to patient outcomes, and directs HHS and GAO to issue guidance, rules, and a study on the effects of VBPAs. The changes are intended to enable outcome-based contracts between manufacturers and States while aligning Medicare and Medicaid price calculations and protecting certain manufacturer-to-State payments from criminal liability if structured as authorized VBPAs. The bill sets deadlines: HHS must issue rulemaking or guidance within 180 days for several provisions, and GAO must report to Congress by June 30, 2029. The act affects State Medicaid programs, Medicaid beneficiaries, Medicare Part B pricing for certain drugs, hospitals for inpatient-administered drugs that are paid separately, and drug manufacturers, with likely effects on payment flows, administrative complexity, and program spending depending on uptake and contract designs.